Overview
Our drug development program has yielded a pipeline of pharmaceutical products and candidates that are focused on the treatment of respiratory and central nervous system disorders. We currently have four U.S. Food and Drug Administration (FDA)-approved drugs on the market as well as earlier-stage compounds for which we plan to conduct proof-of-concept studies. Our pipeline is focused on providing treatments that address large and growing disease states that are served principally by primary care physicians. From insomnia to asthma, to chronic obstructive pulmonary disease (COPD) and depression, Sepracor is seeking ways to improve the lives of the millions of people suffering from these potentially debilitating conditions.